 2. Patients who, during their participation in a previous dupilumab clinical trial, developed an AE that was deemed related to dupilumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient. 